These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 32653806)

  • 1. The landscape of new drugs in extranodal NK/T-cell lymphoma.
    Wang L; Li LR; Zhang L; Wang JW
    Cancer Treat Rev; 2020 Sep; 89():102065. PubMed ID: 32653806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of extranodal NK/T-cell lymphoma: From past to future.
    Yan Z; Yao S; Wang Z; Zhou W; Yao Z; Liu Y
    Front Immunol; 2023; 14():1088685. PubMed ID: 36825002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel Immunotherapy Options for Extranodal NK/T-Cell Lymphoma.
    Hu B; Oki Y
    Front Oncol; 2018; 8():139. PubMed ID: 29761078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary site and regional lymph node involvement are independent prognostic factors for early-stage extranodal nasal-type natural killer/T cell lymphoma.
    Niu SQ; Yang Y; Li YY; Wen G; Wang L; Li ZM; Wang HY; Zhang LL; Xia YF; Zhang YJ
    Chin J Cancer; 2016 Apr; 35():34. PubMed ID: 27044275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel prognostic model based on ferritin and nomogram-revised risk index could better stratify patients with extranodal natural killer/T-cell lymphoma.
    Liu X; Liang Y; Shen Z; Wei L; Yang J; Piao Y; Sang W; Li P; Wang L
    Cancer Med; 2023 May; 12(9):10660-10671. PubMed ID: 36924334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term Outcome of Extranodal NK/T Cell Lymphoma Patients Treated With Postremission Therapy Using EBV LMP1 and LMP2a-specific CTLs.
    Cho SG; Kim N; Sohn HJ; Lee SK; Oh ST; Lee HJ; Cho HI; Yim HW; Jung SE; Park G; Oh JH; Choi BO; Kim SW; Kim SW; Chung NG; Lee JW; Hong YS; Kim TG
    Mol Ther; 2015 Aug; 23(8):1401-1409. PubMed ID: 26017177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LncRNA BCYRN1-induced autophagy enhances asparaginase resistance in extranodal NK/T-cell lymphoma.
    Wang L; Yang J; Wang HN; Fu RY; Liu XD; Piao YS; Wei LQ; Wang JW; Zhang L
    Theranostics; 2021; 11(2):925-940. PubMed ID: 33391513
    [No Abstract]   [Full Text] [Related]  

  • 8. The correlation of clinicopathological features and prognosis in extranodal natural killer/T cell lymphoma: a report of 42 cases in the early stage.
    Zeng L; Huang W; Cao Z; Zheng B; Liu X; Guo L; Feng X
    Ann Hematol; 2019 Jun; 98(6):1467-1476. PubMed ID: 30895352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiotherapy improves survival in early stage extranodal natural killer/T cell lymphoma patients receiving asparaginase-based chemotherapy.
    Li YY; Feng LL; Niu SQ; Wang HY; Zhang LL; Wang L; Xia ZJ; Huang HQ; Xia YF; Zhang YJ; Wang XC
    Oncotarget; 2017 Feb; 8(7):11480-11488. PubMed ID: 28002792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison analysis of first-line asparaginase- versus non-asparaginase-based regimens for early-stage extranodal NK/T-cell lymphoma.
    Qi F; Xie Y; Wang D; Chai Y; Chen B; Sun Y; Liu W; Qi S; Wei Y; Fang H; Zhao D; Gui L; Yang Y; Feng X; Ding N; Mi L; Shu S; Li Y; Song Y; Dong M; Zhu J
    Ann Hematol; 2022 Sep; 101(9):2021-2034. PubMed ID: 35798977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk-based, response-adapted therapy for early-stage extranodal nasal-type NK/T-cell lymphoma in the modern chemotherapy era: A China Lymphoma Collaborative Group study.
    Qi SN; Yang Y; Zhang YJ; Huang HQ; Wang Y; He X; Zhang LL; Wu G; Qu BL; Qian LT; Hou XR; Zhang FQ; Qiao XY; Wang H; Li GF; Zhu Y; Cao JZ; Wu JX; Wu T; Zhu SY; Shi M; Xu LM; Yuan ZY; Su H; Song YQ; Zhu J; Hu C; Li YX
    Am J Hematol; 2020 Sep; 95(9):1047-1056. PubMed ID: 32449800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Advances in immunotherapy of extranodal NK/T cell lymphoma].
    Hao DQ; Li LQ; Li MC; Gong LL
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2019 Dec; 54(12):949-953. PubMed ID: 31887826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selection of new immunotherapy targets for NK/T cell lymphoma.
    Lv K; Li X; Yu H; Chen X; Zhang M; Wu X
    Am J Transl Res; 2020; 12(11):7034-7047. PubMed ID: 33312349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early radiotherapy has an essential role for improving survival in patients with stage I-II nasal-type of NK/T cell lymphoma treated with L-asparaginase-containing chemotherapy--a single institution experience.
    Zang J; Li C; Luo SQ; Wang JH; Xu M; Zhao LN; Li WW; Yang H; Xiao F; Hitchcock YJ; Shi M
    Ann Hematol; 2015 Apr; 94(4):583-91. PubMed ID: 25409913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum EBV EA-IgA and VCA-IgA antibodies can be used for risk group stratification and prognostic prediction in extranodal NK/T cell lymphoma: 24-year experience at a single institution.
    Huang Y; Rao H; Yan S; Wang F; Wu Q; Feng Y; Zhang Y
    Ann Hematol; 2017 Aug; 96(8):1331-1342. PubMed ID: 28550598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Challenges in overcoming advanced-stage or relapsed refractory extranodal NK/T-cell lymphoma: meta-analysis of individual patient data.
    Kim TY; Kim TJ; Han EJ; Min GJ; Jeon Y; Cho SG
    Front Oncol; 2024; 14():1362367. PubMed ID: 39144825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II prospective study of the "Sandwich" protocol, L-asparaginase, cisplatin, dexamethasone and etoposide chemotherapy combined with concurrent radiation and cisplatin, in newly diagnosed, I/II stage, nasal type, extranodal natural killer/T-cell lymphoma.
    Jiang M; Zhang L; Xie L; Zhang H; Jiang Y; Liu WP; Zhang WY; Tian R; Deng YT; Zhao S; Zou LQ
    Oncotarget; 2017 Jul; 8(30):50155-50163. PubMed ID: 28404973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EBV-associated NK and T-cell lymphoid neoplasms.
    Kimura H; de Leval L; Cai Q; Kim WS
    Curr Opin Oncol; 2022 Sep; 34(5):422-431. PubMed ID: 35900729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extranodal NK/T-cell lymphoma, nasal type, with extranasal presentation - a case report and a review of the literature.
    Akbar M; Clasen-Linde E; Specht L
    Acta Oncol; 2020 Dec; 59(12):1480-1487. PubMed ID: 32689856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extranodal natural-killer T-cell lymphoma: experience from China.
    Wang L; Wang JW
    Lancet Haematol; 2020 Jun; 7(6):e441. PubMed ID: 32470431
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.